Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06002828 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

StatusActive, Not Recruiting
PhaseNot specified
Started2023-10-13
View on ClinicalTrials.gov ↗
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma or leukemia. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma or leukemia may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.

Amendment history 6 changes detected by DataLookout

2026-09-16
Enrollment closed, study ongoing
2026-09-16
Primary endpoint(s) modified
WasComorbidities (including symptoms, late effects), Disease free survival (DFS), Overall survival (OS)
NowImpact of social-environmental risk factors on changes in Charlson Comorbidity Index (CCI)
2026-09-16
Trial sites expanded: 428 → 507 locations
2026-09-16
Primary completion moved earlier: 2030-02-01 → 2027-03-31
2026-09-16
Completion moved earlier: 2030-02-01 → 2027-03-31
2026-09-16
Interventions modified
Trial Details
NCT Number NCT06002828
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Enrollment 2,000 participants
Start Date 2023-10-13
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-15